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Summary
 
Experimental autoimmune encephalomyelitis (EAE) is a T cell–mediated autoimmune demy-
elinating disease of the central nervous system that serves as an animal model for multiple scle-
rosis. Antigen-specific tolerance regimens, including oral tolerance, have been used prophylac-
tically to prevent development of acute EAE as well as a number of other autoimmune diseases.
Two mechanisms have been proposed to explain the immunologic basis for disease inhibition:
bystander immune suppression and clonal anergy/deletion. This report demonstrates a novel
mechanism for monocyte chemotactic protein (MCP)-1 as a regulatory factor of oral tolerance.
Oral administration of proteolipid protein peptide (PLP139–151) increased MCP-1 expression
in the intestinal mucosa, Peyer’s patch, and mesenteric lymph nodes. Increase in MCP-1 ex-
pression resulted in downregulation of mucosal interleukin (IL)-12 expression with concomi-
tant increase in mucosal IL-4 expression. Functionally, MCP-1 upregulation was shown to
regulate oral tolerance induction by the ability of antibodies to MCP-1 to inhibit tolerance in-
duction. The anti–MCP-1 abrogation of oral tolerance induction also resulted in restoration of
mucosal IL-12 expression as well as peripheral antigen-specific T helper cell 1 responses. These
results demonstrate a novel and important role for MCP-1 in the regulation or oral tolerance
for the prevention and treatment of autoimmune disease.
 
E
 
xperimental autoimmune encephalomyelitis (EAE)
 
1
 
 is
a CD4
 
1
 
 T cell–mediated, demyelinating disease of the
central nervous system (CNS) that serves as a model for the
human disease, multiple sclerosis (MS; 1). EAE can be in-
duced in animals by immunization with proteolipid protein
(PLP), the encephalitogenic peptide sequence 139–151
(PLP139–151) emulsified in CFA (2), or alternatively by
the adoptive transfer of antigen-activated PLP139–151–
specific T cells to normal recipient mice (3). Characteristics
of the disease include progressive ascending clinical paraly-
sis followed by periods of remission and subsequent relapses
in the SJL/J mouse (4). Analysis of mononuclear cell infil-
tration in the CNS has revealed that antigen-specific and
nonspecific CD4
 
1
 
 and CD8
 
1
 
 T cells as well as macrophages
constitute the recruited cell population (5, 6).
Peripheral, antigen-specific tolerance can be induced by
oral antigen administration and has been used to prevent
the induction of experimental autoimmune diseases (for re-
view see reference 7). The mechanism of oral tolerance is
not completely understood. Earlier studies demonstrated
that antigen feeding induced both anergy and regulatory T
cells (8–10). More recently, it was reported that high dose
antigen feeding resulted in the induction of anergy/dele-
tion (11), whereas feeding of multiple low doses of antigen
induced regulatory T cells that secrete TGF-
 
b
 
 (12, 13).
Even though delivery of antigen through the intestinal mu-
cosa appears to inhibit peripheral cell–mediated immune
responses, this mode of antigen introduction can prime
both mucosal and peripheral antibody responses (14, 15).
Events at the intestinal mucosa that modulate antigen
uptake and processing (e.g., inhibition of oral tolerance in-
duction by introduction of cholera toxin and antigen) also
influence whether oral exposure to antigen induces periph-
eral tolerance or primes a peripheral immune response (16,
17). This latter information suggests that modulation of
mucosal immune responses at the time of antigen feeding is
a central feature in the ability to establish peripheral toler-
 
1
 
Abbreviations used in this paper:
 
 CNS, central nervous system; EAE, exper-
imental autoimmune encephalomyelitis; MCP, monocyte chemotactic
protein; MIP, macrophage inflammatory protein; MLN, mesenteric
lymph node; MS, multiple sclerosis; NRS, normal rabbit serum; PLP,
proteolipid protein; RANTES, regulated on activation normal T cell ex-
pressed and secreted; RT, reverse transcriptase.
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ance through oral antigen administration. Whether this in-
volves increased lymphocyte trafficking or regulatory cy-
tokine modulation is not well understood. Jung et al. (18)
demonstrated that the chemokine MCP-1 is expressed in
the mucosa after infection with bacteria, thereby suggesting
that oral introduction of antigen can result in the upregula-
tion of mucosal chemokine production.
Chemokines such as macrophage inflammatory protein
1
 
a
 
 (MIP-1
 
a
 
), MCP-1, IL-8, and RANTES (regulated on
activation normal T cell expressed and secreted cytokine)
are molecules that induce leukocyte accumulation in tissue
sites of inflammation (19). CC chemokine family members
have been implicated as candidates in the immunopathol-
ogy of EAE, with T cell production of MIP-1
 
a
 
 and T cell
activation gene 3 (TCA-3) shown to be required for induc-
tion of EAE (20). Additionally, MIP-1
 
a
 
 and MCP-1 pro-
duction in the CNS have been associated with acute disease
symptoms in both rat (21) and murine (22–24) EAE mod-
els. These examples raise the possibility that chemokine
production in the CNS of MS patients functions to drive
pathogenesis of disease through the recruitment of leuko-
cytes into the brain.
In addition to regulating leukocyte migration, chemo-
kines appear to have additional functions. Recently, chemo-
kine-induced signaling in human T cells has been demon-
strated (25). Moreover, Taub et al. (26) have demonstrated
a role for chemokines in costimulation resulting in en-
hanced IL-2 production as well as proliferation of T cell
clones. Similarly, we have shown that chemokines can reg-
ulate T cell differentiation (27) and cytokine production
(28). Chemokine expression at the intestinal mucosa as well
as mucosal lymphoid tissue could affect leukocyte traffick-
ing and/or differentiation of T helper lymphocyte effector
function, thereby influencing peripheral immune respon-
siveness. It is well documented that immune tolerance and
thus prevention of autoimmune disease can be achieved by
prefeeding intact autoantigenic proteins (for review see ref-
erence 29); however, the immunologic mechanisms are not
well understood. Therefore, this study was designed to ex-
plore the immune regulatory role of MCP-1 after oral anti-
gen administration.
 
Materials and Methods
 
Animals.
 
Female SJL/J mice were purchased from Harlan
Sprague Dawley (Indianapolis, IN). Mice were 6–7 wk old at the
initiation of the experiment and were maintained on standard
laboratory chow and water ad libitum. Animal care was provided
in accordance with Northwestern University and National Insti-
tutes of Health (Bethesda, MD) guidelines.
 
Antigens.
 
PLP139–151 (HSLGKWLGHPDKF) was purchased
from Peptides International (Louisville, KY). The amino acid
composition was verified by mass spectrometry and purity (
 
.
 
98%)
was assessed by HPLC. Theiler’s virus VP2 70-86 was synthesized on
an ABI Synergy machine (Perkin Elmer, Norwalk, CT) according
to the manufacturer’s instructions and used as the control peptide.
 
Antibodies.
 
Rabbit anti–murine MIP-1
 
a
 
, MCP-1, and MIP-2
antibodies were prepared by multiple site immunization of New
Zealand white rabbits with recombinant proteins (R&D Systems,
Minneapolis, MN) emulsified in CFA. Polyclonal antibodies
were titered by direct ELISA and specificity was verified by the
failure to cross-react with murine (m)IL-1
 
a
 
, mIL-2, mTNF, IL-6,
human (h)IL-8, hRANTES, and hMIP-1. Moreover, the individ-
ual chemokine antibodies do not cross-react with other murine
chemokines (e.g., anti–MCP-1 does not cross-react with MIP-
1
 
a
 
). At the time of the experiments the titer of the antichemo-
kine antibodies was 
 
.
 
10
 
6
 
. Normal rabbit serum (NRS) was used
as a control immunoglobulin preparation for in vivo treatment
regimens. Antichemokine antibodies were injected into individ-
ual mice from different treatment groups either intraperitoneally
or intravenously with no functional differences between the two
routes of administration observed.
 
Active EAE Induction and Clinical Disease Assessment.
 
EAE was
induced as previously described (4). In brief, each mouse received
a subcutaneous injection of 0.1 ml emulsion containing 87 
 
m
 
g (50
nmol) PLP139–151 and 200 
 
m
 
g 
 
Mycobacterium tuberculosis
 
 H37Ra
in IFA (Difco, Detroit, MI) at three sites on the dorsal flank. Dis-
ease onset usually occurs within 3 wk of immunization and was
assessed by observing individual animals daily, and clinical sever-
ity as follows: grade 0, no abnormality; grade 1, limp tail; grade 2,
limp tail and partial hind limb weakness (waddling gait); grade 3,
complete hind limb paralysis; grade 4, death. A relapse was scored
when a mouse developed additional neurological deficits (
 
>
 
1
clinical grade) after a period of stabilization or improvement.
 
Cell Culture.
 
Single cell suspensions from pooled lymph nodes
or spleens were cultured at a density of 2.5 
 
3
 
 10
 
6
 
 cells/ml in
DMEM containing 5% FCS, 1 mM glutamine, 100 U/ml peni-
cillin, 100 
 
m
 
g/ml streptomycin, 1 mM nonessential amino acids
and 5 
 
3
 
 10
 
2
 
5
 
 M 2-ME (complete DMEM-5; all components
from Sigma Chemical Co., St. Louis, MO) in the presence or ab-
sence of 50 
 
m
 
g/ml PLP peptides.
 
Chemokine and Cytokine ELISA.
 
Assessment of MCP-1 was
quantitated from tissue samples using previously described ELISAs
(30, 31). Mucosal samples were homogenized in 1 ml PBS and
clarified by centrifugation (400 
 
g
 
) for 10 min. Flat-bottomed mi-
crotiter plates (Nunc, Naperville, IL) were coated with capture
antibody diluted to 3.2 
 
m
 
g/ml in borate-buffered saline coating
buffer and were incubated overnight. Nonspecific binding sites
were blocked with 2% BSA in PBS for 1 h at 37
 
8
 
C and samples
were subsequently added in triplicate for 2 h at 37
 
8
 
C. Biotiny-
lated goat anti–rabbit detection antibody was added and the plates
were incubated for an additional 1 h at 37
 
8
 
C. The wells were de-
veloped using strepavidin-peroxidase and 
 
o
 
-phenylenediamine
substrate and absorbence was read at 490 nm. Standard curves for
MCP-1 were generated using a series of dilutions of purified re-
combinant protein (R&D Systems). Chemokine levels in mucosa
were quantitated by comparison to the standard curves and ex-
pressed as pg/mg tissue. The detection limit of these assays is at
least 25 pg/ml. The MCP-1 ELISA is specific and does not cross-
react with any other chemokine or cytokine. The presence of IL-12
and IL-4 in tissue samples was quantitated using cytokine-specific
ELISA performed as follows: microwell plates were coated with ei-
ther anti–IL-12 (5 
 
m
 
g/ml) or anti–IL-4 (1 
 
m
 
g/ml) mAb (Phar-
Mingen, San Diego, CA) in Dulbecco’s PBS overnight at 4
 
8
 
C.
Nonspecific binding was reduced by blocking with PBS contain-
ing 2% BSA for 1 h at room temperature. The microwell plates
were washed with 50 mM Tris 0.2% Tween 20 and dilutions of
recombinant IL-12 or IL-4 (PharMingen) as well as the appropri-
ate experimental samples were added and incubated overnight at
4
 
8
 
C. Either goat anti–IL-12 (20 
 
m
 
g/ml) or goat anti–IL-4 (10
 
m
 
g/ml; R&D Systems) was added and the plates were incubated
for 2 h at room temperature. The wells were developed using 
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peroxidase-conjugated donkey anti–goat IgG (Jackson Immunore-
search, West Grove, PA) and 3,3
 
9
 
,5
 
9
 
,5
 
9
 
-tetramethylbenzidine di-
hydrochloride (TMB) substrate (DAKO Corp., Carpinteria, CA).
The reaction was stopped by adding 0.18 M H
 
2
 
SO
 
4
 
 and the ab-
sorbence was read at 450 nm. Experimental samples were com-
pared to standard curves for both IL-12 and IL-4, which were
generated using a series of dilutions of recombinant protein. The
data was expressed as picogram of cytokine per milligram tissue.
Antigen-induced cytokine production was assayed from 48 h (for
IL-4 and IFN-
 
g
 
) culture supernatants after stimulation with 50
 
m
 
g/ml PLP139–151. Duplicate samples were tested for the pres-
ence of IFN-
 
g
 
 and IL-4 (Endogen, Cambridge, MA), and the
data were expressed as picogram per milliliter when compared to
recombinant standards. TGF-
 
b
 
 was analyzed from supernatants of
cells grown in serum-free medium or in tissue samples using a
modified ELISA protocol as previously described (12).
 
Results
 
Mucosal MCP-1 Production after Oral Antigen Administra-
tion.
 
We asked whether MCP-1 is expressed at mucosal
tissue and lymphoid sites after introduction of oral antigen.
Jung et al. (18) reported that infection of intestinal epithe-
lium resulted in expression of an array of proinflammatory
cytokine expression, including MCP-1. We have previ-
ously shown that feeding 2 mg of PLP-139–151 peptide
inhibits development of EAE and induces clonal anergy as
measured by a decrease in antigen-specific IL-2 and IFN-
 
g
 
production in the absence of measurable TGF-
 
b
 
 produc-
tion (32). Inhibition of EAE by feeding PLP139–151 pep-
tide is dose dependent as progressively smaller single as well
as multiple doses of fed peptide failed to inhibit develop-
ment of EAE (our unpublished data). Additionally, induc-
tion of oral tolerance using this single-dose peptide regi-
men has never resulted in an increase in TGF-
 
b
 
 expression
above that of background in antigen-specific restimulation
of lymphocytes (32). In our experiments, mice were fed 2 mg
of either PLP139–151 or control peptide once and 7 d later
were immunized for EAE induction with PLP139–151
emulsified in CFA. Samples of proximal intestinal mucosa
were harvested immediately after antigen feeding as well as
at days 3, 8, 10, 14, 17, and 24 after oral administration of
antigen. The tissue was homogenized and subsequently as-
sayed for the presence of MCP-1 by ELISA. We have suc-
cessfully used this approach to assay CNS tissue for the
presence of chemokines (22). The results shown in Fig. 1
indicate that mucosal MCP-1 expression increased after
oral administration of PLP139–151 (
 
closed circles
 
) and con-
tinued to increase in fed mice that were primed with
PLP139–151 in CFA (
 
arrow
 
). These levels of MCP-1 are
significantly greater (
 
P
 
 
 
,
 
0.05 as indicated by 
 
asterisks
 
) than
in control peptide-fed mice primed with PLP139–151 in
CFA (
 
closed squares
 
). Saline-fed mice did not show a level of
MCP-1 expression above the detection limit of the assay
(data not shown).
 
Peyer’s Patch and Mesenteric Lymph Node Expression of
MCP-1 after Oral Antigen Administration.
 
Antigens absorbed
through the mucosal epithelium and Peyer’s patches drain
into the mesenteric lymph node (MLN) and portal circula-
tion (7). We asked whether chemokine expression in the
Peyer’s patch and MLN could be detected after oral anti-
gen administration. We could not detect MIP-1
 
a
 
 expres-
sion in any mucosal tissue by ELISA, immunohistochemis-
try, or reverse transcriptase (RT)-PCR (data not shown),
nor could we detect MCP-1 expression in Peyer’s patch or
MLN by ELISA or immunohistochemistry (data not
shown). However, as shown in Fig. 2, we were able to use
RT-PCR to detect the expression of MCP-1 at early time
points in both Peyer’s patch and MLN after oral antigen
administration. Mice were fed either PLP139–151 or saline
as a control and examined for Peyer’s patch and MLN
MCP-1 expression daily by RT-PCR. MCP-1 was de-
tected in both Peyer’s patch and MLN only in mice fed
PLP139–151 and not in mice fed saline. Mice fed a control
peptide, VP2 70-86, known to bind I-A
 
s
 
 also expressed
MCP-1 in the Peyer’s patch and MLN, but mice fed a
control peptide, ovalbumin 323–339, that does not bind
I-A
 
s
 
 with high affinity did not show mucosal MCP-1 ex-
pression (data not shown). In an effort to determine which
populations of cells in the Peyer’s patch and MLN ex-
pressed MCP-1, cells were separated into plastic adherent
or nonadherent populations and each was subsequently an-
alyzed for expression of MCP-1 by RT-PCR. The plastic
adherent cell population was highly enriched for cells of
the macrophage lineage as determined by Mac-3 immu-
nostaining (data not shown). The results demonstrated that
mucosal expression of MCP-1 was limited to macrophage-
Figure 1. MCP-1 production
in intestinal mucosa after anti-
gen feeding. Mice were fed ei-
ther PLP139–151 or control
peptide and 7 d later were
primed for EAE induction by in-
jection of PLP139–151 in CFA
(arrow). Intestinal mucosa was
harvested from representative
mice at various timepoints after
antigen feeding, homogenized,
and assayed for the presence of
MCP-1 protein by ELISA. The
data represent the mean MCP-1
levels from duplicate assay samples. The data are representative of three
identical experiments. Asterisk, P ,0.05.
Figure 2. Detection of MCP-1
mRNA expression in mucosal
lymphoid tissue after antigen feed-
ing. Mice were fed either
PLP139–151 or control peptide
and both Peyer’s patch and
MLNs were harvested and as-
sayed for MCP-1 mRNA ex-
pression using RT-PCR. Tissue
was harvested at the indicated time points (in days) after oral antigen ad-
ministration. Control MCP-1 mRNA expression (C) was determined
from LPS-stimulated macrophages and used as an internal control for the
RT-PCR conditions. Amplified cDNA was electrophoresed through 2%
agarose gels and visualized using ethidium bromide. The data are repre-
sentative of three identical experiments. 
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enriched adherent cells from either Peyer’s patch or MLN
as shown in Fig. 3 and not to the T cell–enriched nonad-
herent cell populations (data not shown). These results sug-
gest that MCP-1 is expressed by mucosal immune system–
adherent macrophages in response to orally administered
antigen.
 
Oral Administration of PLP139–151 Downregulated Mucosal-
derived IL-12 and Upregualted Mucosal-derived IL-4.
 
Chensue
et al. (33) demonstrated that increased MCP-1 production in a
schistosomiasis model resulted in a decrease in IL-12 pro-
duction by inflammatory macrophages. Additionally, this
report together with our observation that oral administra-
tion of PLP139–151 upregulated mucosal MCP-1 expres-
sion prompted us to examine the levels of IL-12 at the mu-
cosa after oral tolerance induction. Mice were fed either
PLP139–151 or control peptide and proximal intestinal
mucosa as well as spleen was harvested at days 0, 3, 8, 10,
14, 17, 20, and 24 after feeding. Tissue lysates were subse-
quently assayed for the presence of IL-12 and IL-4 by
ELISA. The results shown in Fig. 4 demonstrate that after
oral PLP139–151 administration there was a significant de-
crease in mucosal IL-12 expression (
 
A
 
, 
 
closed circles
 
) over
time when compared to control peptide–fed mice (
 
A
 
, 
 
closed
squares
 
). There was no detectable change in splenic IL-12
production (
 
B
 
). The opposite results were obtained when
the tissue was analyzed for IL-4 content. As shown in Fig.
5, oral administration of PLP139–151 resulted in an in-
crease in mucosal IL-4 production when compared to con-
trol peptide–fed tissue. We could not detect IL-4 produc-
tion in whole splenic lysates after antigen feeding (data not
shown). These results together with those in Fig. 1 suggest
that oral administration of antigen results in an increase in
mucosal MCP-1 and IL-4 expression with a concomitant
decrease in IL-12 expression.
 
Effect of In Vivo Anti–MCP-1 Treatment on Oral Tolerance
Induction.
 
The experimental evidence to this point sug-
gested that oral administration of antigen led to upregula-
tion of MCP-1 and IL-4 accompanied by downregulation of
IL-12. We wanted to determine whether there was a direct
role for MCP-1 in the regulation of oral tolerance induc-
tion as a prevention for EAE. To test the in vivo role of
MCP-1 in tolerance induction, we fed animals either
PLP139–151 or control peptide and treated the recipients
with either anti–MCP-1 or control NRS. The antibody
treatments bracketed the oral antigen administration (i.e., 2 d
before antigen feeding, the day of antigen feeding, and 2 d
after antigen feeding). The results are shown in Fig. 6 
 
A
 
and demonstrate that mice fed control peptide developed
EAE (
 
closed squares
 
), whereas mice fed PLP139–151 failed
to develop acute EAE (
 
closed circles
 
). However, mice treated
in vivo with anti–MCP-1 at the time of PLP139–151 feed-
ing did not develop tolerance, rather they developed severe
clinical EAE (
 
open circles
 
) when compared to the NRS-
treated control group that were fed PLP139–151 and did
not develop severe EAE (
 
closed circles
 
). Anti–MCP-1 treat-
ment itself did not affect the course of EAE development as
demonstrated by the failure of anti–MCP-1 to alter normal
disease course (
 
open squares
 
). These data suggest that MCP-1
plays a functional role in oral tolerance induction.
Since other chemokines such as MIP-1
 
a
 
 and RANTES
have been shown to be associated with EAE (22) as well as
to play a role in T cell activation and cytokine production
(25–27) we tested whether in vivo treatment with antisera
Figure 3. Detection of MCP-1
mRNA expression in the adher-
ent cell populations of mucosal
lymphoid tissue after antigen
feeding. Mice were fed either
PLP139–151 or control peptide
and both Peyer’s patch and
MLNs were harvested. The ad-
herent cells were isolated by plastic adherence (see Materials and Meth-
ods) and assayed for MCP-1 mRNA expression using RT-PCR. Adher-
ent cells were harvested at the indicated time points (in days) after oral
antigen administration. Control MCP-1 mRNA expression (C) was de-
termined from LPS-stimulated macrophages and used as an internal con-
trol for the RT-PCR conditions. Amplified cDNA was electrophoresed
through 2% agarose gels and visualized using ethidium bromide. The data
are representative of three identical experiments.
Figure 4. Il-12 expression in
mucosal tissue and spleen after
oral administration of antigen.
Mice were fed either PLP139–
151 or control peptide and 7 d
later were primed for EAE in-
duction by injection of PLP139–
151 in CFA (arrow). Intestinal
mucosa (A) and spleen (B) were
harvested from representative
mice at various time points after
antigen feeding, homogenized,
and assayed for the presence of
IL-12 protein by ELISA. The
data represent the mean IL-12
levels from duplicate assay sam-
ples. The data are representative
of two identical experiments. As-
terisk, P ,0.05.
Figure 5. IL-4 expression in
mucosal tissue after oral adminis-
tration of antigen. Mice were fed
either PLP139–151 or control
peptide and 7 d later were
primed for EAE induction by in-
jection of PLP139–151 in CFA
(arrow). Intestinal mucosa was
harvested from representative
mice at various time points fol-
lowing antigen feeding, homog-
enized, and assayed for the pres-
ence of IL-4 protein by ELISA.
The data represent the mean IL-4
levels from duplicate assay samples. The data are representative of two
identical experiments. Asterisk, P ,0.05. 
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to these factors at the time of PLP139–151 feeding would
have an effect on oral tolerance induction. Neither anti–
MIP-1a nor anti-RANTES administration abrogated oral
tolerance induction (data not shown). Furthermore, we in-
vestigated the temporal effect of anti–MCP-1 administra-
tion and determined whether treatment with anti–MCP-1
after feeding of PLP139–151 had the same effect as anti-
body treatment at the same time as peptide feeding. Groups
of mice were fed one dose of 2 mg of PLP139–151 or con-
trol peptide and were treated with 0.5 ml anti–MCP-1 or
NRS 3, 5, and 7 d after antigen feeding. All mice were
primed with PLP139–151 emulsified in CFA and observed
for the development of clinical disease signs. The results
shown in Fig. 6 B demonstrate that treatment with anti–
MCP-1 3 d after antigen feeding did not abrogate oral tol-
erance induction. These results further support the idea
that MCP-1 expression at antigen feeding regulates oral
tolerance induction.
Mucosal Cytokine Production after Anti–MCP-1 Treat-
ment. We have demonstrated that anti–MCP-1 treatment
at the time of PLP139–151 feeding abrogated oral toler-
ance (Fig. 6 A) To directly demonstrate the effect of anti–
MCP-1 treatment on mucosal cytokine expression, we
performed an identical experiment to that shown in Fig. 6
A in which mice were treated with anti–MCP-1 or NRS
at the time of antigen feeding. 7 d after antigen feeding,
mice were immunized with PLP139–151 in CFA and 7 d
after that, mice were killed and mucosal IL-12 and IL-4 ex-
pression was measured by ELISA. The results in Fig. 7
show that feeding of PLP139–151 significantly reduced
mucosal IL-12 production (group B, open bar) and en-
hanced mucosal IL-4 production (group B, hatched bar)
when compared to control-fed and control-treated animals
(group A). However, mice fed PLP139–151 and treated
with anti–MCP-1 at the time of oral tolerance induction
(group D, open bar showed a level of mucosal-derived IL-
12 similar to that of the control-fed and control-treated
mice (group A) as well as control-fed and anti–MCP-1-
treated mice (group C). The most important observation
was that anti–MCP-1 treatment at the time of PLP139–151
antigen feeding resulted in significantly enhanced mucosal
IL-12 production compared to mice fed only PLP139–151
(group B, open bar). These results suggest that MCP-1 up-
regulation after antigen-feeding and subsequent antigen
priming result in a decrease in mucosal IL-12 expression
and that neutralization of MCP-1 by in vivo antibody
treatment restored mucosal IL-12 expression.
Effect of Anti–MCP-1 Treatment on Antigen-specific T Cell
Responses. We have previously demonstrated that oral
administration of PLP139–151 inhibited acute EAE devel-
opment, antigen-specific proliferation, IL-2 and IFN-g pro-
duction, and increased IL-4 production (32). Since anti–
MCP-1 abrogated oral tolerance induction (Fig. 6 A) and
reversed the downregulation of mucosa-derived IL-12 pro-
duction (Fig. 7), we asked what the effect of anti–MCP-1
treatment at the time of antigen feeding was on antigen-
specific recall immune responses. Splenic lymphocytes were
harvested from the experiment described in Fig. 7 and
were restimulated in vitro with PLP139–151, and the cul-
ture supernatants were harvested and assayed for the pres-
ence of IL-4 and IFN-g. The results of this experiment are
shown in Fig. 8 and demonstrate that when PLP139–151
Figure 6. In vivo anti–MCP-1 treatment abrogates induction of oral
tolerance (A) Mice were fed either PLP139–151 to induce immunologic
tolerance of control peptide 7 d before disease induction with PLP139–
151 in CFA. Each of those two groups were further divided and treated
with either 0.5 ml anti–MCP-1 or NRS 2 d before antigen feeding, the
day of antigen feeding, and 2 d after antigen feeding. (B) Mice were fed
either PLP139–151 or control peptide 7 d before disease induction with
PLP139–151 in CFA. Each of those two groups was further divided and
treated with either 0.5 ml anti–MCP-1 or NRS 3, 5, and 7 d after antigen
feeding. All animals were followed for the development of clinical EAE
according to the grading scale in the Materials and Methods. The data
represent the mean clinical disease score in each group and are representa-
tive of at least two identical experiments. Animals that were fed PLP139–
151 and treated with NRS (closed circles) developed significantly decreased
clinical disease compared to control peptide–fed and NRS-treated mice
(closed squares), P , 0.05 days 17–25 after immunization.
Figure 7. Il-4 and IL-12 expression in mucosal tissue after oral admin-
istration of antigen and in vivo anti–MCP-1 treatment. Mice were fed ei-
ther PLP139–151 to induce immunologic tolerance or control peptide 7 d
before disease induction with PLP139–151 in CFA. Each of those two
groups was treated with either 0.5 ml anti–MCP-1 or NRS 2 d before
antigen feeding, the day of antigen feeding, and 2 d after antigen feeding
(similar to the experiment in Fig. 2). 7 d after disease induction, intestinal
mucosa was harvested and analyzed for the presence of IL-4 and IL-12.
The data represent either the mean IL-4 or IL-12 levels from duplicate as-
say samples. The data are representative of two identical experiments.738 MCP-1 Regulation of Oral Tolerance
was fed to mice before EAE induction, antigen-specific
IFN-g production was significantly decreased (open bar,
group  B versus group A) and IL-4 production was slightly
increased (hatched bar, group B versus group A). However,
anti–MCP-1 treatment in vivo given at the time of antigen
feeding prevented downregulation of IFN-g production
(open bar, group D versus group B), effectively returning
the response to that of control-fed and -treated (open bar,
group A). We could not detect a significant change in
TGF-b production (data not shown). These data suggest
that anti-MCP-1 treatment in vivo prevented the down-
regulation of IFN-g that normally results from oral toler-
ance induction (reference 32 and Fig. 8), possibly by restor-
ing IL-12 levels to that of normal control. Collectively, our
data argue for a mechanism of oral tolerance induction that
includes mucosal expression of MCP-1, which regulates
mucosal expression of IL-12.
Discussion
Oral antigen administration has been shown to induce
peripheral T cell tolerance in a number of antigen and ex-
perimental disease systems. The mechanism of oral toler-
ance induction is not completely understood and two hy-
potheses have emerged to explain the differences reported
in the literature (13). The first is feeding high doses of solu-
ble antigen, which results in clonal anergy and/or deletion
(11). The second hypothesis offered to explain oral toler-
ance induction is the generation of an antigen-specific T
cell population that has the capacity to secrete regulatory
cytokines, including TGF-b, that downregulate antigen-
specific immune responses in the absence of clonal anergy
or deletion (34). Oral tolerance using intact neuroantigens
and neuroantigen peptides has been employed primarily for
the prevention of EAE by prefeeding animals followed by
active induction of disease by immunization with neuroan-
tigen in CFA (35, 36). It was only recently demonstrated
that oral administration of MBP could treat ongoing
chronic EAE in the B10.PL mouse (37), and that oral ad-
ministration of the dominant collagen epitope could treat
ongoing experimental arthritis (38); however, oral adminis-
tration of the dominant PLP epitope, PLP139–151, failed
to alter ongoing relapsing EAE in the SJL mouse model
(39). The focus of oral tolerance mechanisms in these au-
toimmune disease models has been on the antigen-specific
peripheral lymphocyte. In this report we described a novel
mechanisms for mucosal cytokine regulation leading to the
induction of oral tolerance.
MCP-1 is expressed by mucosal epithelia cells after in-
fection with a number of bacteria (18) and can be expressed
by macrophages (40). After oral administration of PLP139–
151, MCP-1 expression was upregulated in the mucosal
immune tissue, including the mucosa, Peyer’s patch, and
MLN (Fig. 1–3). The levels of MCP-1 in the mucosa re-
main elevated and continue to rise in tolerized mice after
immunization with PLP139–151 and CFA compared to the
control-fed group (Fig. 1). We have not yet determined
the mucosal cell type responsible for MCP-1 production
after antigen feeding, but it appears that Peyer’s patch–
derived adherent Mac-31 cells express MCP-1 after anti-
gen feeding (Fig. 3). MCP-1 regulation of oral tolerance
was shown to be biologically relevant by the ability of in
vivo anti–MCP-1 treatments to abrogate oral tolerance in-
duction at the time of antigen feeding (Fig. 6 A). The inhi-
bition of tolerance induction by anti–MCP-1 treatment
was specific as treatment regimens beginning 3 d after anti-
gen feeding had no effect on tolerance induction (Fig. 6 A)
and anti–MIP-1a and anti-RANTES treatment at the time
of antigen feeding also had no effect on tolerance induction
(data not shown). MCP-1 regulation of oral tolerance in-
duction may function through two distinct mechanisms.
The first is that MCP-1 directly upregulates IL-4 expres-
sion, which potentiates differentiation of Th2 cells (27).
The molecular basis for MCP-1–induced Th2 differentia-
tion is unknown, but currently under investigation. After
antigen feeding and upregulation of MCP-1 expression in
the mucosal immune compartment, Peyer’s patch and
MLN T cells may be predisposed to differentiate into Th2
cells or alternatively, MCP-1 expression could potentiate
IL-4 production, which would drive peripheral Th2 differ-
entiation (41).
The second possible mechanism postulates that MCP-1
expression could directly downregulate IL-12 production,
which could result in a partial or complete block of periph-
eral Th1 differentiation (41) and/or enhancement of mu-
cosal TGF-b expression (42), which in turn could result in
an increase or enhancement of TGF-b–secreting regulatory
cells (34). We favor the possibility that MCP-1 expression
is regulating Th1 differentiation and/or TGF-b regulation
based on the reports that oral tolerance can be induced in
IL-4–deficient mice (43) and that treatment with anti–IL-4
does not inhibit the ability to induce oral tolerance (32).
Our data suggesting that MCP-1 downregulation of mu-
Figure 8. Effect of in vivo anti–MCP-1 treatment on antigen-specific
IL-4 and IFN-g production. Splenic lymphocytes were harvested from
the experimental groups shown in the figure and were cultured with
PLP139–151 in vitro, and the supernatants were harvested and subse-
quently assayed for the presence of IL-4 and IFN-g by ELISA. The data
are representative of two identical experiments.739 Karpus et al.
cosal IL-12 expression is central to oral tolerance induction
is supported by observations from others demonstrating
that orally administered IL-12 promotes a systemic antigen-
specific Th1 response (44). The combination of inhibiting
Th1 differentiation and potentiating Th2 differentiation
may explain oral tolerance induction and why blocking
these events with in vivo anti–MCP-1 administration abro-
gates tolerance induction (Fig. 6 A).
Another possible mechanism of MCP-1 regulation of
oral tolerance induction involves T cell and/or macrophage
trafficking in response to a chemotactic gradient. MCP-1
has been shown to induce T cell migration (45) and its up-
regulation in the mucosa after antigen feeding may pro-
mote infiltration of T cells into the mucosal immune tis-
sues. These T cells may be preferentially activated to
secrete TGF-b, migrate to the CNS, and become effector
regulatory cells that downregulate EAE (46). Additionally,
MCP-1 expression in the mucosa may induce migration of
macrophages (47) to the site of antigen uptake and then
present the fed antigen to T cells in the mucosal immune
tissue. Alternatively, after migration of macrophages into
the mucosal site of antigen uptake, the macrophages may
migrate to peripheral immune tissue and present antigen to
T cells, resulting in either induction of regulatory T cells or
direct inactivation of pathogenic Th1 cells (43). Therefore,
administration of neutralizing antibodies to MCP-1 in vivo
would preclude the ability of mucosal-derived MCP-1 to
induce T cell or macrophage migration.
The significance of MCP-1 expression in the mucosal
lymphoid tissue after antigen feeding is not completely un-
derstood. MIP-1a, MIP-1b, and RANTES expression was
not detected in the mucosa, Peyer’s patch, or MLN after
feeding of either PLP139–151, control peptide, or a non–I-
As binding peptide (data not shown). It is interesting to
note that although feeding a control peptide induced a
quantitatively smaller mucosal MCP-1 response, it did not
induce oral tolerance (Figs. 1 and 6). This suggests that there
is a multilevel control of tolerance induction with a level of
antigen specificity as well as a level of cytokine/chemokine
regulation. The observation that mucosal MCP-1 expres-
sion is elevated after a bolus of fed antigen may reflect the
constant regulation of immune responses to food antigens.
This report describes an additional regulatory mechanism
involved in oral tolerance induction that can be further
manipulated to produce a more efficient and long-lasting
immune tolerance during autoimmune disease. For exam-
ple, enhancement of mucosal MCP-1 expression at the
time of antigen feeding may be able to provide efficacious
tolerance induction that would not be possible by antigen
feeding alone. We are currently exploiting the possibilities
for the development of more effective tolerogenic regi-
mens for the treatment of ongoing autoimmune disease.
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